Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 8/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753409 | 0.85 | FFAR1 (0.35) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL21201415 | 0.85 | LPL (0.37) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL16009725 | 0.85 | FFAR1 (0.35) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL30523101 | 0.84 | FFAR1 (0.40) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL16008825 | 0.84 | FFAR1 (0.40) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL22185786 | 0.83 | LPL (0.40) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL23597018 | 0.82 | FFAR1 (0.44) | DGAT1FFAR1LPLLIPGHIF1A | |
| SCHEMBL406138 | 0.80 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL29506948 | 0.80 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL24023348 | 0.79 | LPL (0.37) | DGAT1FFAR1LPLLIPGHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | CAPULUS THERAPEUTICS, LLC | 2021-02-18 | — | — | US | disclosed |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | CAPULUS THERAPEUTICS, LLC | 2021-02-18 | — | — | US | disclosed |
| CN-112243374-A | SREBP inhibitors comprising a 6-membered central ring | 卡普勒斯疗法有限责任公司 | 2021-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | DGAT1 1192/4885FFAR1 810/4885LPL 450/4885 |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | SREBF1, SREBF2, XBP1 | DGAT1 1192/4885FFAR1 810/4885LPL 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.